Myriad RBM, of Austin, Tex, recently launched immunoassay services based on Quanterix’s ultrasensitive Simoa single molecule array platform, which enables users to accurately measure difficult-to-detect protein biomarkers in blood samples.
“The Simoa platform is an exciting new tool that is 100 to 1,000 times more sensitive than conventional tests for blood-based protein biomarkers and will open up new avenues of clinical research,” says Ralph McDade, president of Myriad RBM. “We believe Simoa will significantly accelerate biomedical discoveries by providing researchers with valuable insights into both the underlying mechanisms of disease and the safety and efficacy of pharmaceuticals.”
At first, the Simoa assay services will be used to study inflammatory and autoimmune diseases. Specifically, Myriad has manufactured and validated Simoa-based quantitative immunoassays for interleukin-6 and tumor necrosis factor alpha—both available from the company’s CLIA-certified laboratory. The assays are equipped with calibrators and controls that are designed to provide multiple precise measurements.
Myriad aims to add more Simoa-based immunoassays on an ongoing basis.
“Understanding the incredible role of quantifying ultra-low concentrations of protein biomarkers in human blood samples and their linkage to the complex mechanisms of a disease has the potential to revolutionize the field of medicine as we know it,” says Kevin Hrusovsky, executive chairman of Quanterix. “We are very pleased to be collaborating with Myriad RBM and to be working together to provide access to these important new developments in healthcare.”
For more information, visit Myriad RBM.
